About
Marc Olivier Perret joined Gilde in 2000 from Ciba/Novartis. Prior to joining in October 2000, Marc Olivier gained operational and international experience during 17 years at the Novartis (Ciba) Group, in business development, restructuring, as country division head and ultimately as M&A Head of one of Novartis’ divisions. His track record includes a $ 1 billion acquisition of a Merck & Co division, direct involvement in the multi-billion merger and listing of Switzerland-based Syngenta, and several smaller biotechnology deals. Marc Olivier Perret is an engineer from École Centrale de Lyon and received an M.B.A. from HEC Group/Stanford Graduate School of Business. He is a French national and speaks English, Italian and Spanish. Marc Olivier led investments in Conatus Pharmaceuticals, Innate Pharma (listed at Euronext) and Neuro3D (merged) and represents Gilde on the board of Conatus (IPO on NASDAQ). Former board representations include CropDesign, Neuro3d and Innate Pharma.
Position in the VCSift Database
- • 23 investors at Gilde Healthcare are tracked.
- • 5 investors hold the Managing Partner role in VCSift. Marc Olivier Perret is one of them.
- • 113 investors are based in Utrecht, Utrecht, The Netherlands.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Utrecht, The Netherlands
Contact Information
Find more investors like Marc
Search Investors